After the successful development of mavacamten and the sale of MyoKardia to BMS in 2020, former executives of the biotech are ...

A new biotech start-up – Ouro Medicines – launched today with $120 million in funding from a Series A and a plan to develop ...

Boston-area startup Mediar Therapeutics is teaming up with Eli Lilly on a new drug for idiopathic pulmonary fibrosis. Lilly — ...

Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases, today announced its launch with $120 million in funding. The ...

Ouro is planning to leverage T cell engagers to deplete B cells and “reset” the immune system to treat immune-mediated ...

T cell engagers are having a moment, much like antibody-drug conjugates have for the past two years. The cell-depleting ...

Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ...

NEW YORK (PIX11) — A young man, homeless and disheveled, was surrounded by a joint response team made up of two NYPD officers ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. | The Fierce Biotech Fundraising Tracker records ...

But their shine is beginning to dull. Now investors are setting their sights on Yeti Ouro (YETIO), the latest viral altcoin to storm the market. Yeti Ouro is racing up the investor watchlists with its ...

The content and materials featured on this page are for educational purposes only. Yeti Ouro storms the crypto scene with a sold-out presale, 40% early returns, and a P2E gaming platform set to spark ...

The group will coordinate planning around future use of the site, the breadth of options for support to staff and agreeing next steps for the local investment of a £2m legacy donation by GSK.